Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Assets Average (2016 - 2025)

Historic Assets Average for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to $460.5 million.

  • ImmunityBio's Assets Average rose 1386.68% to $460.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $460.5 million, marking a year-over-year increase of 1386.68%. This contributed to the annual value of $443.7 million for FY2024, which is 237.39% up from last year.
  • Latest data reveals that ImmunityBio reported Assets Average of $460.5 million as of Q3 2025, which was up 1386.68% from $352.9 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Assets Average registered a high of $468.4 million during Q4 2023, and its lowest value of $215.4 million during Q1 2021.
  • Moreover, its 5-year median value for Assets Average was $353.7 million (2022), whereas its average is $358.0 million.
  • In the last 5 years, ImmunityBio's Assets Average surged by 9927.55% in 2022 and then plummeted by 2413.34% in 2025.
  • Over the past 5 years, ImmunityBio's Assets Average (Quarter) stood at $341.7 million in 2021, then increased by 4.68% to $357.6 million in 2022, then skyrocketed by 30.98% to $468.4 million in 2023, then decreased by 20.21% to $373.8 million in 2024, then rose by 23.22% to $460.5 million in 2025.
  • Its last three reported values are $460.5 million in Q3 2025, $352.9 million for Q2 2025, and $343.3 million during Q1 2025.